vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (... vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. 더 보기
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER PR Newswire WESTON, Fla., Dec. 9, 2024 WESTON, Fla., Dec. 9...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.25 | 1.8115942029 | 13.8 | 14.35 | 13.2 | 10070 | 13.60836842 | CS |
4 | -0.7744 | -5.22382018834 | 14.8244 | 15.262 | 13.2 | 9124 | 13.95485167 | CS |
12 | -0.79 | -5.32345013477 | 14.84 | 18.37 | 12.62 | 27666 | 15.13936044 | CS |
26 | -9.65 | -40.7172995781 | 23.7 | 24.82 | 12.1201 | 29421 | 15.8105679 | CS |
52 | 5.38 | 62.0530565167 | 8.67 | 30.99 | 7.38 | 35700 | 16.29010605 | CS |
156 | -20.814 | -59.7005507113 | 34.864 | 56 | 7.38 | 168372 | 28.76745202 | CS |
260 | -74.35 | -84.1063348416 | 88.4 | 205.2 | 7.38 | 890906 | 99.7320467 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관